Journal of Clinical Oncology
Articles in this Issue
Readmissions after CNS tumor surgery and associations with social determinants of health.
e14040 Background: Socioeconomic status (SES) and social determinants of health (SDOH) may impact outcomes in patients wit...
Subtype-specific PI3K-pathway and TP53 alteration patterns in breast cancer: A cross-cohort comparison of TCGA-BRCA and AACR GENIE.
e13011 Background: The PI3K pathway is among the most actionable signaling axes in breast cancer, yet its alteration frequ...
Interstitial lung disease risk and outcomes across HER2-targeted therapies commonly used in breast cancer: Analysis of real-world FAERS data.
e24206 Background: Anti-HER2 therapies, including the monoclonal antibody Trastuzumab and antibody-drug conjugates (ADCs)...
Digital symptom monitoring using Careology at Guy’s and St Thomas’ NHS Foundation Trust (GSTFT).
e13715 Background: Careology is a digital health platform for cancer patients receiving Systemic Anti-Cancer Therapy, enab...
The future mortality trends in multiple myeloma (SEER analysis 2000–2030).
7550 Background: Novel therapies have transformed Multiple Myeloma (MM) from a rapidly fatal diagnosis into a chronic cond...
Early-onset colorectal cancer trends and risk exposures in Ghana and the United States: A comparative ecological analysis based on Global Burden of Disease, 2023.
e15691 Background: Early-onset colorectal cancer (EOCRC), defined as colorectal cancer (CRC) diagnosis before age 50, is i...
Exploring the effects of T cell senescence in RCC and HGSOC.
e16542 Background: T cell senescence is an emerging mechanism of immune dysfunction characterized by impaired proliferatio...
Untargeted baseline metabolomic profiling to identify candidate markers of long-term severe cancer-related fatigue (CRF) in breast cancer (BC) survivors.
12118 Background: CRF is common and debilitating among BC survivors; however its predictors and underlying biology remain...
Safety, PK/PD, and efficacy results from Expand-1: A phase 1 dose escalation study of the novel PD-1 targeted IL-2R-βγ agonist sunekafusp alpha (ANV600) as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
2587 Background: Sunekafusp alpha (ANV600) is a novel PD-1-targeted, IL- 2Rβ/γ agonist, which binds, without blocking, a u...
Whole-genome profiling to identify chromosomal instability as a distinct feature of lung cancer brain metastases.
e20554 Background: Brain metastases in lung cancer are associated with substantial clinical heterogeneity and poor outcome...
Clinical utility of liquid <i>KRAS</i> -mutation screening in advanced pancreatic cancer patients referred for early-phase trials.
3049 Background: Approximately 90% of pancreatic ductal adenocarcinomas (PDAC) harbor a KRAS mutation. Clinical trials tar...
Orbital cancer: Historical trends in histological composition and cause-specific mortality based on SEER database analysis.
e18138 Background: Malignant orbital tumors are rare cancers encompassing a broad spectrum of lymphoid and epithelial hist...
De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study.
e12512 Background: Treatment of stage I HER2-positive breast cancer has shifted toward increased use of taxane-only chemot...
Overall survival of Black patients with newly diagnosed multiple myeloma in the era of triplet and quadruplet therapies.
11055 Background: Black individuals have been shown to have a higher incidence of multiple myeloma, as well as worse survi...
Impact of proton pump inhibitors on the pathological complete response rate in luminal breast cancer during neoadjuvant therapy.
e12631 Background: Breast cancer (BC) is one of the most prevalent neoplasms, with a prognosis dependent on hormonal recep...
Prognostic indicators and socioeconomic disparities in teratoma with malignant transformation: An NCDB analysis.
e22613 Background: Teratomas with malignant transformation (TMT) are rare germ cell tumors in which a typically benign mat...
Durvalumab plus platinum-etoposide in extensive-stage extrapulmonary small cell carcinoma (ES-EPSCC): Second safety assessment of the DURVASCC trial (GOIRC-01-2021).
e14572 Background: EPSCC is a rare and highly aggressive malignancy with a poor prognosis. The low incidence has limited p...
Bridging the gap between clinical utility and coverage: Real-world impact of unreimbursed NGS testing.
11194 Background: Genomic testing is the cornerstone of precision oncology, revealing rare yet clinically actionable alter...
Spatial RNA–protein profiling of antibody–drug conjugate (ADC) targets in leiomyosarcoma (LMS).
11509 Background: LMS remains a therapeutically challenging sarcoma with limited targeted options. Although ADCs are a pro...
Correlation of ten-year survival with cell-free DNA methylation of melanoma patients with asymptomatic brain metastases treated with nivolumab plus ipilimumab: The multicenter phase III NIBIT-M2 trial.
2008 Background: The NIBIT Foundation-sponsored phase III NIBIT-M2 study showed a 41% 7-y OS of melanoma patients (pts) wi...
Prediction of localized rectal cancer outcomes with ctDNA analysis using a novel ultrasensitive structural variant (SV)-based method.
3619 Background: Rectal cancer has a high risk of recurrence and incidence is rising. Treatment for rectal cancer has move...
Mammogram energy use: Metering to map optimization strategies.
e12714 Background: Mammography is a critical component of screening and diagnosis in breastcancer. A key component of canc...
Comparative effectiveness of adjuvant TACE versus HAIC after curative resection for high-risk BCLC 0–B hepatocellular carcinoma: A three-center retrospective study.
e16253 Background: Recurrence remains a major challenge following curative resection for early-to-intermediate stage hepat...
A retrospective real-world study on the efficacy and safety of anlotinib in combination with immunotherapy as maintenance therapy after standard immunochemotherapy for extensive-stage small cell lung cancer (ALTER-L059).
8080 Background: Although immune checkpoint inhibitors (ICIs) combined with chemotherapy have become the standard first-li...
Early circulating tumor DNA dynamics as a prognostic and predictive biomarker in solid tumors treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
e15091 Background: Early identification of patients likely to benefit from immune checkpoint inhibitors (ICIs) remains a m...